Evonik Evonik

X

Find Drugs in Development News & Deals for Lysergide D-tartrate

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

0

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

EU WC

EU WC

0

Listed Suppliers

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

MM-120 (lysergide D-tartrate) is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at 5-HT2A receptors. It is being evaluated for the treatment of generalized anxiety disorder.


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 07, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 14, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of Attention-Deficit/Hyperactivity Disorder.


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 24, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MM-120 (lysergide D-tartrate) is a psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A), which is investigated for the treatment of generalized anxiety disorder.


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead candidate MM-120 (lysergide D-tartrate), which is currently in Phase 2 for generalized anxiety disorder.


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Mind Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement August 03, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MM-120 (lysergide D-tartrate) is a semi-synthetic hallucinogen or recreational drug, which is being investigated in patients with generalized anxiety disorder (GAD).


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 25, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MM-120 (lysergide D-tartrate) is a semi-synthetic hallucinogen or recreational drug, which is being investigated in patients with generalized anxiety disorder (GAD)


Lead Product(s): Lysergide D-tartrate

Therapeutic Area: Psychiatry/Psychology Product Name: MM-120

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 17, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY